TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04344704

Intervention type: OTHER
Intervention: Single chamber DAI device with floating atrial dipole
Description: DAI for the detection of atrial signals with optimized programming, using Smart, Onset \& Stability, and Morphmatch methods

Intervention type: OTHER
Intervention: Single chamber DAI device with floating atrial dipole
Description: DAI for the detection of atrial signals with optimized programming, using Smart, Onset \& Stability, and Morphmatch methods
Study: NCT00826488

Intervention type: DEVICE
Group type: OTHER
Intervention: Digital Breast Tomosynthesis
Description: Women with a positive screening mammogram called back for additional views will be asked to undergo an additional Digital Breast Tomosynthesis (3D mammogram) on the affected breast. Radiation dose is somewhat less than that of a screening mammogram.
Study: NCT02366793

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accessory joint mobilization
Description: Three kinds of humeral head slides: anterior, posterior and caudal slides. Subjects remained in supine position during the whole treatment. The techniques were applied in a rhythmical way, with 2 seconds of slide/traction and then a 2-second break. Each technique was carried out for 2 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve mobilization
Description: Neural tissue longitudinal slide using the median neurodynamic test 1 (MNT1) that was described by Butler. The proximal parameters (scapular depression, abduction and humeral external rotation) were introduced with maximum neural tension. On the other hand, the distal parameters (supination, elbow extension, wrist and fingers extension) received the remaining tension that the neural tissue allowed. The parameters were introduced sequentially in the order exposed
Study: NCT04026945

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Description: Sustained-release lidocaine injection
Study: NCT04399057

Intervention type: DIAGNOSTIC_TEST
Intervention: shear Wave Elastosonography
Description: both the left cavernous body and the right cavernous body are ideally divided longitudinally into three sections: proximal, middle and distal. subsequently for each section of the corpora cavernosa the stiffness of the tissue is calculated by means of a specific Region Of Interest (ROI). the result is expressed in Kilopascals and in a color scale. when registering the stiffness the patient is asked to hold their breath.
Study: NCT03554304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 5222
Description: FEP-ZID IV solution administered as either a 30- or 60-minute IV infusion)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV placebo matched to WCK 5222 / Moxifloxacin IV solution
Description: Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo matched to WCK 5222 / Moxifloxacin IV solution
Description: Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV placebo matched to WCK 5222 / Moxifloxacin IV solution
Description: Placebo (IV placebo matched to FEP-ZID IV solution) and~1 placebo capsule matched to moxifloxacin overencapsulated tablet
Study: NCT03771313

Intervention type: DRUG
Group type: OTHER
Intervention: Ceftaroline
Description: Patients will have intravenous ceftaroline dosed according to current recommendations based upon its approved usage in pediatric patients for community acquired pneumonia. Blood samples will be collected for PK/PD analysis.
Study: NCT03554304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400-mg
Description: Moxifloxacin 400-mg positive control (overencapsulated tablet)
Study: NCT02574767

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine diet & PA
Description: Obese pregnant women from PHCC randomized to this group will receive will receive routine diet \& PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Routine diet & PA
Description: Obese pregnant women from PHCC randomized to this group will receive will receive routine diet \& PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PUFA placebo
Description: Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PUFA placebo
Description: Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
Study: NCT01113190

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adapted Motivational Enhancement Therapy (AMET)
Description: This session will have a similar general outline to the sessions conducted in the ED, including a review of participants' goals and values, and a review of their substance use and consequences, use of decisional balance exercises as indicated, and review and modification of their change plan. For the AMET intervention, the intervener (at least master's level) will conduct a single session (\~30-45 minutes) in the community (HMC ED or our community research office). The therapist will be able to tailor their approach to each individual's needs and motivational state.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.
Study: NCT04448366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Patients in the CBT group will receive usual care. In addition, they will undergo one pre-surgery and six post-surgery face-to-face sessions of CBT. In the pre-surgery session, management of expectations towards surgery will be addressed. In the six post-surgery sessions, attention will be paid to psycho-education concerning the biological link between endometriosis-related pain and stress, relaxation training, cognitive stress management, and management of anxiety, catastrophizing and hypervigilance. The CBT sessions will be coordinated by a registered psychotherapist who is experienced in CBT and has knowledge about endometriosis. All CBT will be individual sessions.
Study: NCT01948661

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mirtoselect® + Meriva®

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02038972

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cells
Description: The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
Study: NCT01113177

Intervention type: DEVICE
Intervention: Distraction splint therapy
Description: After the diagnosis of unilateral TMJ arthritis with clinical asymmetric mandibular growth deviations the JIA patients are offered treatment with a distraction splint. The appliance consists of an acrylic splint (distraction splint) covering the occlusal surfaces of the teeth in the upper or lower dental arch. The height of the splint is thereafter gradually increased every 6th to 10th weeks in order to optimize the mandible growth in the affected side and thereby reduce the overall asymmetric mandibular growth pattern(non-surgical distraction of the TMJ and mandibular condyle).
Study: NCT03763695

Intervention type: OTHER
Intervention: Measures for the VAP prevention in the PICU
Description: Oral hygiene care (i.e chlorhexidine swab); clean and dry ventilator circuits; head positioning at 45 degrees.

Intervention type: OTHER
Intervention: Evaluation of VAP incidence before the protocol introduction
Description: evaluation of VAP incidence in our pediatric population of intensive care patients before the implementation of the protocol for VAP prevention
Study: NCT02977429

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: standardized fluid therapy
Description: The patients with ScvO2 \<70% will receive the standardized fluid therapy for 6 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional fluid therapy
Description: The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.
Study: NCT02679937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit4Duty
Description: Small (\<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
Study: NCT04540588

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Description: An intratumoral insertion of a seed(s), loaded with Radium-224, securely fixed in the seeds. The seeds release by recoil into the tumor short-lived alpha-emitting atoms.
Study: NCT02679937

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education
Description: Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
Study: NCT02676895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVGH S. sonnei (1790GAHB) vaccine 25 μg
Description: Two injections of the study vaccine were administered 28 days apart.
Study: NCT03238755

Intervention type: OTHER
Intervention: Cardiac MRI/MRS
Description: whole blood, plasma, and serum

Intervention type: OTHER
Intervention: Cardiac MRI/MRS
Description: whole blood, plasma, and serum
Study: NCT01113190

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.
Study: NCT01336595

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zirconium (Zirconium Genesis II)
Description: Oxidized Zirconium femoral component of Genesis II TKR system is used.
Study: NCT02669771

Intervention type: DRUG
Intervention: enzalutamide
Description: oral
Study: NCT02676895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVGH S. sonnei (1790GAHB) vaccine 100 μg
Description: Two injections of the study vaccine were administered 28 days apart.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menveo
Description: One injection of Menveo was administered in subjects in the Control Group.
Study: NCT01336595

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cobalt-Chrome (Cobalt Chrome Genesis II)
Description: Cobalt Chrome Femoral Component of Genesis II TKR system is used
Study: NCT03115125

Intervention type: OTHER
Group type: OTHER
Intervention: Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 of hospitalization in medical reanimation.
Description: Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 (or on leaving the service if before D14) of hospitalization in medical reanimation.
Study: NCT02057068

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SLEEP-E Dyads Intervention
Description: Described in arm/group description
Study: NCT01128166

Intervention type: DEVICE
Intervention: COGNIS CRT-D
Description: Patients with existing or newly implanted COGNIS® CRT-D pulse generators (PG)are enrolled in the study. PG is modified by the download of investigational software called Sensor Research Device-1™ (SRD-1). The goal of the SRD-1 system is to collect sensor data without affecting the delivered CRT-D therapy. This is accomplished through the conversion of an implanted COGNIS PG into a SRD-1 PG by downloading investigational software. Only a market approved COGNIS model N119/N120/P107/P108 device may be converted to a SRD-1 investigational device. There will be no PG hardware changes resulting from the conversion.
Study: NCT03625297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shelter cat
Description: families will adopt a shelter cat
Study: NCT03385408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIRO® 3.0
Description: Patients will receive pulsed Nd:YAG (yttrium aluminum garnet) laser, produced by HIRO 3.0 device (ASA, Vicenza, Italy). The total energy deliver to the patient during one session will be 3.000 J through three phases of treatment. HILT will be applied for a total of 4 weeks (three sessions/week).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser
Description: For sham laser, the patient will attended the physical therapy clinic three times a week for 4 weeks and receive sham laser. It is applies the same time than experimental one but with 0 W.
Study: NCT03256097

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voice Track
Description: Voice Track is a cochlear implant noise cancellation system which is designed to reduce the adverse effect of background noise on speech perception through cochlear implants
Study: NCT00210405

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sprinkles containing mulitple micronutrients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education/communication on use of micronutrient sprinkles

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fortified food aid (corn-soy blend)
Description: This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified food aid (corn-soy blend)
Description: This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.
Study: NCT00319553

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
Description: 0.5 mL, IM

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed
Description: 0.5 mL, IM
Study: NCT06062082

Intervention type: PROCEDURE
Intervention: adrenalectomy
Description: laparoscopic exeresis of the adrenal gland

Intervention type: PROCEDURE
Intervention: adrenalectomy
Description: laparoscopic exeresis of the adrenal gland
Study: NCT04978961

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focused Acceptance & Commitment Therapy (FACT)
Description: FACT is a brief form of Acceptance and Commitment Therapy and in this study, FACT focused on increasing patient functioning through connection with valued activities and increased acceptance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Description: This active control intervention included 4 handouts focused on pain management based on cognitive behavioral science.
Study: NCT01896102

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Lenti-D Drug Product (eli-cel)
Description: Participants received a single IV infusion of Lenti-D Drug Product.
Study: NCT02892578

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electrocardiogram
Study: NCT01725503

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Creatine and Amino Acid supplement
Study: NCT01502930

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IRT
Description: Internet-based IRT with therapist support during 6 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Reduction
Description: Internet-based stress reduction with therapist support during 6 weeks
Study: NCT02042183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 12 or 24 mcg soft capsules of lubiprostone for oral administration, depending on baseline weight and response during week 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mcg soft capsules of placebo for oral administration
Study: NCT02084654

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide 5 and 10 mcg 2 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02235909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azilsartan Medoxomil Low-dose
Study: NCT04282876

Intervention type: DRUG
Intervention: Degarelix
Description: Patients receiving Degarelix
Study: NCT02676895

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix
Description: One injection of Boostrix was administered in subjects in the Control Group.
Study: NCT02311036

Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive Rehabilitation
Description: Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.

Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive Rehabilitation
Description: Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.

Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive Rehabilitation
Description: Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.

Intervention type: OTHER
Group type: OTHER
Intervention: Comprehensive Rehabilitation
Description: Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.
Study: NCT03365687

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 2 mL of 50,000 IU/mL at baseline and at 3.5 months with a daily dose of 1 mL (400 IU/mL) for 7 months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 mL of placebo at baseline and at 3.5 months with a daily dose of placebo (1 mL) for 7 months
Study: NCT03029039

Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples will be collected at inclusion.
Study: NCT01317693

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity shock waves
Description: 1500 shocks, Energy Density - 0.09 mJ/mm2
Study: NCT04414527

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard counselling
Description: The control cohort will receive national standard counseling during four ante-natal care visits.~Women in the control group will receive additionally~1. national nutrition and health care including IFA supplementation,~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health-Video
Description: The intervention cohort Health-Video will receive innovative video-based nutritional and hygienic education.~Women in this group will receive additionally:~1. National nutrition and health care including IFA supplementation~2. treatment of any symptomatic health condition and deworming in case of symptomatic complaints during second and third trimesters,~3. Women who experience odor, itching or discharge will be treated for candidiasis and bacterial vaginosis.
Study: NCT04152746

Intervention type: OTHER
Intervention: Periostin level
Description: The serum periostin levels were planned to compare between the serum samples that were obtained from the two groups. The evaluation of the periostin levels of adenoid tissue and normal healthy mucosa were also planned.

Intervention type: OTHER
Intervention: Periostin level
Description: The serum periostin levels were planned to compare between the serum samples that were obtained from the two groups. The evaluation of the periostin levels of adenoid tissue and normal healthy mucosa were also planned.